Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

11.51 -0.14 (-1.20%)
Streaming Delayed Price Updated: 2:59 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. ↗
The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions. 
Via Investor's Business Daily
News headline image
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment ↗
FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors. 
Via Benzinga
News headline image
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
News headline image
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray ↗
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
Via Investor's Business Daily
News headline image
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 ↗
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
Via Benzinga
News headline image
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.